In the last trading session, 1.14 million shares of the Corcept Therapeutics Inc (NASDAQ:CORT) were traded, and its beta was 0.34. Most recently the company’s share price was $67.43, and it changed around -$1.19 or -1.73% from the last close, which brings the market valuation of the company to $7.11B. CORT currently trades at a discount to its 52-week high of $117.33, offering almost -74.0% off that amount. The share price’s 52-week low was $20.84, which indicates that the current value has risen by an impressive 69.09% since then. We note from Corcept Therapeutics Inc’s average daily trading volume that its 10-day average is 2.55 million shares, with the 3-month average coming to 1.49 million.
Corcept Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CORT as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Corcept Therapeutics Inc is expected to report earnings per share of 0.14 for the current quarter.
Corcept Therapeutics Inc (NASDAQ:CORT) trade information
Instantly CORT has showed a red trend with a performance of -1.73% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 77.85 on recent trading dayincreased the stock’s daily price by 13.38%. The company’s shares are currently up 33.82% year-to-date, but still down -9.67% over the last five days. On the other hand, Corcept Therapeutics Inc (NASDAQ:CORT) is 20.39% up in the 30-day period. We can see from the shorts that 16.53 million shares have been sold at a short interest cover period of 9.7 day(s).
The consensus price target as assigned by Wall Street analysts is $80, which translates to bulls needing to increase their stock price by 15.71% from its current value. Analyst projections state that CORT is forecast to be at a low of $80 and a high of $80.
Corcept Therapeutics Inc (CORT) estimates and forecasts
The year-over-year growth rate is expected to be 34.12%, up from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 177.93M in revenue for the current quarter. 4 analysts expect Corcept Therapeutics Inc to make 216.68M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 146.81M and 163.8M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 21.20%. Forecasts for the next quarter put sales growth at 32.28%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 9.89%. Corcept Therapeutics Inc earnings are expected to increase by 37.80% in 2025, but the outlook is positive 70.53% per year for the next five years.
CORT Dividends
Corcept Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-25.
Corcept Therapeutics Inc (NASDAQ:CORT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 11.44% of Corcept Therapeutics Inc shares, and 81.37% of them are in the hands of institutional investors. The stock currently has a share float of 91.88%. Corcept Therapeutics Inc stock is held by 495.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 16.0391% of the shares, which is about 16.54 million shares worth $537.36 million.
VANGUARD GROUP INC, with 9.2943% or 9.55 million shares worth $310.4 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
